Showing results (1-10 of 333) with videos related to
Sort By:
Pageof 34
Best Practice & Research. Clinical Haematology|April 1, 2019
Myeloid disorders after autoimmune diseasePrajwal C Boddu, Amer M ZeidanExpert Review of Anticancer Therapy|August 20, 2019
Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemiaRory M Shallis, Jan Philipp Bewersdorf, Prajwal C Boddu, et al.Blood Reviews|November 26, 2019
The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemiaRory M Shallis, Prajwal C Boddu, Jan Philipp Bewersdorf, et al.Blood Reviews|December 30, 2019
The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemiaJan Philipp Bewersdorf, Rory M Shallis, Prajwal C Boddu, et al.European Journal of Haematology|November 1, 2018
Molecular pathogenesis of acquired aplastic anemiaPrajwal C Boddu, Tapan M KadiaExpert Review of Hematology|March 10, 2017
Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trendsMaximilian Stahl, Amer M ZeidanCells|July 27, 2022
Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic SyndromesYasmin Abaza, Amer M ZeidanBlood and Lymphatic Cancer : Targets and Therapy|July 9, 2025
Advancing AML Treatment: Evidence-Based Regimens and Guideline Updates for Targeted Treatments in R/R AML [Podcast]Amer M Zeidan, Eunice WangCancer|February 14, 2017
Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applicationsMaximilian Stahl, Amer M ZeidanBlood Reviews|August 21, 2022
CHIPing away the progression potential of CHIP: A new reality in the makingZhuoer Xie, Amer M ZeidanPageof 34